Pancreatic Cancer Research

ResearcherZhejiang Chinese Medical UniversityActive in the last 2 years

Nengming Lin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-5202-802X; OpenAlex author ID A5054183094. Sources: OpenAlex.

Their work

Papers
4 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
0
Collaborators
8
Papers, trials and grants by year

2020: 1 paper · 2021: none · 2022: 1 paper · 2023: none · 2024: none · 2025: none · 2026: 2 papers

Papers 4

  1. Discovery of Novel ERK5 Inhibitors for Pancreatic Cancer via a Virtual Screening Approach. Last author DOI 10.1021/acsmedchemlett.5c00547↗
  2. The Effect of AZD5153 on Radiosensitivity in Pancreatic Cancer Cells Through ATM-chk1 Pathway. Co-author DOI 10.2147/dddt.s568551↗
  3. Inhibition of TRIM32 by ibr-7 treatment sensitizes pancreatic cancer cells to gemcitabine via mTOR/p70S6K pathway. Last author DOI 10.1111/jcmm.17109↗
  4. A novel derivative of valepotriate inhibits the PI3K/AKT pathway and causes Noxa-dependent apoptosis in human pancreatic cancer cells. Co-author DOI 10.1038/s41401-019-0354-1↗

Closest collaborators

The 8 strongest of 8 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Lulin Zhu · 1 shared paper, 2026 · strength 0.30
  2. Bei Tan · 1 shared paper, 2026 · strength 0.30
  3. Rong Dong · 1 shared paper, 2026 · strength 0.30
  4. Jingyu Zhang · 1 shared paper, 2026 · strength 0.28
  5. Youyou Yan · 2 shared papers, 2020–2022 · strength 0.27
  6. Bo Zhang · 1 shared paper, 2022 · strength 0.15
  7. Jing Chen · 1 shared paper, 2020 · strength 0.12
  8. Bo Zhang · 1 shared paper, 2020 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.